Company: PTPI
Filing Date: 2025-02-13
Form Type: S-1/A
Source: 0001410578-25-000122
Chunk: 6

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-13
Form: S-1/A
Chunk 6
---
269 per share of common stock used throughout this prospectus may not be indicative of the actual public offering price for our Units. There is no established public trading market for each of the Series Warrants or the Pre-Funded Warrants, and we do not expect a market to develop. In addition, we do not intend to apply for the listing of either of the Series Warrants or the Pre-Funded Warrants on any national securities exchange. Without an active trading market, the liquidity of the Series Warrants and the Pre-Funded Warrants will be limited.

We will have one closing for all the securities purchased in this offering. The public offering price per Unit will be fixed for the duration of this offering.

#### This offering will terminate on          , 2025, unless we decide to terminate the offering (which we may do at any time in our discretion) prior to such date. We will have one closing for all the securities purchased in this offering. The public offering price per Unit will be fixed for the duration of this offering.We may sell fewer than all securities offered hereby, which may significantly reduce the amount of proceeds received by us, and investors in this offering will not receive a refund if we do not sell all of the securities offered hereby. We have not established an escrow account in conjunction with this offering. Because there is no escrow account and no minimum number of securities or amount of proceeds, investors could be in a position where they have invested in us, but we have not raised sufficient proceeds in this offering to adequately fund the intended uses of the proceeds as described in this prospectus.PerShare of Common Stock andSeries WarrantsPer Pre-FundedWarrant andSeries WarrantsTotalPublic offering price​$​$​$​Placement Agent fees(1)​​​​​​​Proceeds, before expenses, to us(2)​$​$​$​(1)We have agreed to pay Dawson James a total cash fee equal to 8% of the aggregate gross proceeds raised in this offering and to reimburse Dawson James for its legal fees and expenses and other out-of-pocket expenses in an amount up to $125,000. See “Plan of Distribution” for a description of the compensation to be received by Dawson James.(2)Because there is no minimum number of securities or amount of proceeds required as a condition to closing in this offering, the actual public offering amount, placement agent fees, and proceeds to us, if any, are not presently determinable and may be substantially less than the total maximum offering amounts